Transcription
You ever heard of a stock going to $40 from 20? Yes, you heard it right. This stock could be the one that achieves that feat because 3 years ago, this was a $40 stock. Last month, it traded for just 20 cents a share. And right now, it is sitting on one of the rarest setups I have ever seen in the entire market.
This is a tiny pharmaceutical company the market completely left for dead. The FDA rejected their drug, not once, twice. For most companies, that is the end of the story. Lights out. Go home. But then something happened that almost never happens. The FDA reversed itself.
The stock is OTLK, Outlook Therapeutics. Here is the simple version of what they do. They make an eye injection that treats wet AMD, a disease that slowly destroys the central vision of older people, the part you use to read, to recognize faces, to see a screen. And here is the key. Their drug is a cleaned up eye specific version of a medicine doctors already use and already trust for this exact problem today. They are just using it off label. Outlook wants the official FDA stamp so insurance companies pay for it. Same medicine doctors already believe in just finally with the government's blessing on the box.
Now here is what just happened that makes this so explosive. On June 1st, Outlook resubmitted their application to the FDA. This followed their successful appeal after which the FDA's own office of new drugs concluded that substantial evidence of effectiveness had been established and no additional trials were required. The FDA itself directed its staff to finalize the product labeling. And here is the part that makes this tradable. The resubmission is classified as a class one review with an FDA decision expected within 60 days, not the typical 6 months. 60 days. The clock is already running and answer is expected by early August.
And this is not some unproven science experiment. The drug already holds marketing authorization in the EU and UK with commercial launches already underway in Germany, Austria, and the UK. Regulators across the Atlantic already looked at this exact drug and said, "Yes." The whole company is valued at under $90 million right now. If that last domino falls and the FDA approves, the move on a company this small could be substantial.
But understand the risk. The FDA could say no. Again, this is speculative. When the news hits, the move is instant. You have to be positioned before the decision, not after. A real drug already approved overseas, a known 60-day window. This is what a once-in-a-lifetime catalyst looks like.